| Jumia Technologies AG: Jumia Shareholders Elect New Supervisory Board, Deepening African Expertise as Company Targets 2027 Profitability | Shareholders elected Jonathan D. Klein, Anne Ooga Eriksson, Hassanein Hiridjee, Benjamin T. Faw, and Dr. Akinwumi Ayodeji Adesina - former President of the African Development Bank - at the 2026 Jumia... ► Artikel lesen |
| Jumia Technologies AG: Jumia Reports First Quarter 2026 Results | Jumia Reports 32%[1] GMV Growth and 39% Revenue Increase; Adjusted EBITDA Loss Narrowed 32%, Reflecting Continued Progress Toward Profitability; Jumia Reaffirms 2026 Guidance LAGOS, NIGERIA / ACCESS... ► Artikel lesen |
| Jumia Technologies AG: Jumia to Announce First Quarter 2026 Results on May 7, 2026 | LAGOS, NIGERIA / ACCESS Newswire / April 27, 2026 / Jumia Technologies AG (NYSE:JMIA) ("Jumia") today announced that it will release results for the first quarter 2026 before the U.S. market opens on... ► Artikel lesen |
| Abivax-Aktie: Bericht bestätigt neue Übernahmegespräche | Die Übernahmefantasie rund um Abivax erhält neue Impulse. Nachdem zuletzt mehrere Analysten ihre Kursziele für die Aktie angehoben und auf das erhebliche Potenzial des Wirkstoffkandidaten Obefazimod... ► Artikel lesen |
| Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update | Valerio and Abivax enter into a binding term-sheet for an exclusive global research and development collaboration Under the terms of the agreement Valerio will receive an upfront payment... ► Artikel lesen |
| Abivax-Aktie: Analysten erhöhen Prognosen - diese Woche Übernahmeknall? | Die Abivax-Aktie bleibt einer der spannendsten Biotech-Werte des Jahres. Nachdem Reuters zuletzt bestätigt hatte, dass der französische Wirkstoffentwickler mit mehreren Interessenten über eine mögliche... ► Artikel lesen |
| CSE Bulletin: Consolidation - Adaptogenics Health Corp. (ADPT) | Le 13 juillet/July 2026
Adaptogenics Health Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated share for four (4) pre-consolidated... ► Artikel lesen |
| Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses | SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune... ► Artikel lesen |
| Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics... ► Artikel lesen |